Apimeds Pharmaceuticals US, Inc. (APUS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the APUS SEC filings page.
This page shows Apimeds Pharmaceuticals US, Inc. (APUS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest figures show an equity-funded business whose operations consume cash, while financing inflows support its enlarged balance sheet.
In FY2025, the net loss was$6.0M while operating cash flow was-$8.9M , so reported earnings understated the cash absorbed by operations. Free cash flow was-$9.0M against only$57K of capital spending, locating almost all cash use in operations rather than asset reinvestment.
FY2025 liabilities were
Financing cash flow of
Financial Health Signals
Apimeds Pharmaceuticals US, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Apimeds Pharmaceuticals US, Inc. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $6.0M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Apimeds Pharmaceuticals US, Inc. reported an operating loss of $11.9M against $283K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Apimeds Pharmaceuticals US, Inc.'s EBITDA was -$6.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 135.5% from the same quarter a year earlier. Against the prior quarter it is up 48.4%.
Apimeds Pharmaceuticals US, Inc. reported -$20.2M in net income in Q2 2026. This represents a decrease of 657.8% from the same quarter a year earlier. Against the prior quarter it is up 42.5%.
Apimeds Pharmaceuticals US, Inc. earned -$11.77 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Apimeds Pharmaceuticals US, Inc. recorded an outflow of $5.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is down 172.8%.
Apimeds Pharmaceuticals US, Inc. held $278K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Apimeds Pharmaceuticals US, Inc.'s ROE was -18.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 8.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Apimeds Pharmaceuticals US, Inc. invested $960K in research and development in Q2 2026. This represents an increase of 47.2% from the same quarter a year earlier. Against the prior quarter it is up 6.5%.
Apimeds Pharmaceuticals US, Inc. reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
APUS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $960K+47.2% | $901K | N/A | $620K | $652K | N/A | N/A | N/A |
| SG&A Expenses | $5.3M+164.3% | $11.3M+2997.0% | N/A | $1.2M+308.2% | $2.0M+370.4% | $364K+34.1% | N/A | $300K |
| Operating Income | -$6.3M-135.7% | -$12.2M-3244.3% | N/A | -$1.8M-514.7% | -$2.7M-522.8% | -$364K-34.1% | N/A | -$300K |
| EBITDA | -$6.3M-135.5% | -$12.2M | N/A | N/A | -$2.7M | N/A | N/A | N/A |
| Interest Expense | $3.2M+104499.4% | $8K-99.0% | N/A | $6K-80.7% | $3K-86.1% | $851K+3062.7% | N/A | $33K |
| Net Income | -$20.2M-657.8% | -$35.1M-8612.8% | N/A | -$1.8M-435.7% | -$2.7M-492.4% | -$402K-35.7% | N/A | -$333K |
| EPS (Basic) | -$11.77-358.0% | -$2.26-4420.0% | -$0.08-100.0% | -$0.14-250.0% | -$2.57-4183.3% | -$0.05-25.0% | -$0.04 | -$0.04 |
| EPS (Diluted) | -$11.77 | -$2.26 | -$0.08-100.0% | -$0.14 | -$2.57 | -$0.05-25.0% | -$0.04 | -$0.04 |
| Diluted Shares (Avg) | 2M | 16M | N/A | 13M | 1M | 8M0.0% | N/A | 8M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
APUS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $127.6M+1110.1% | $141.2M+54235.1% | $164.2M+1257338.4% | $9.3M | $10.5M | $260K | $13K-96.9% | N/A |
| Current Assets | $10.7M+3.2% | $13.2M+4960.8% | $14.0M+106998.6% | $9.1M | $10.3M | $260K | $13K-96.9% | N/A |
| Cash & Equivalents | $278K-96.8% | $980K+291.1% | $1.6M+47270.6% | $7.0M+26194.1% | $8.7M+13694.2% | $250K+69.9% | $3K-99.2% | $27K |
| Short-Term Investments | $0 | $1.5M | $2.0M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $21.2M+2517.4% | $14.7M+627.8% | $10.8M+690.3% | $1.1M | $809K | $2.0M | $1.4M+251.4% | N/A |
| Current Liabilities | $21.1M+2504.8% | $14.6M+723.8% | $10.7M+945.2% | $1.1M | $809K | $1.8M | $1.0M+730.7% | N/A |
| Non-Current Liabilities | $102K | $119K-52.5% | $129K-62.7% | $0 | $0 | $250K | $347K+30.0% | N/A |
| Total Equity | $106.4M+993.2% | $126.5M+7286.3% | $153.3M+11391.2% | $8.2M+879.8% | $9.7M+1463.9% | -$1.8M-565.3% | -$1.4M-4361.6% | -$1.0M |
| Retained Earnings | -$65.6M-780.1% | -$45.5M-848.1% | -$10.4M-136.6% | -$9.2M | -$7.5M | -$4.8M | -$4.4M-46.3% | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
APUS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.7M-68.6% | -$2.1M-10079.3% | -$3.8M | -$1.7M-824.3% | -$3.4M-1726.1% | -$20K+92.3% | N/A | -$187K |
| Depreciation & Amortization | $5K+1909.5% | $20K | $4K | N/A | $232 | N/A | N/A | N/A |
| Stock-Based Compensation | $105K-45.2% | N/A | N/A | N/A | $192K | $0 | N/A | N/A |
| Capital Expenditures | $0 | $9K | $21K | $23K | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$5.7M | -$2.1M | -$3.8M | -$1.7M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $1.5M | $491K | -$10.0M | -$23K | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $3.5M-70.8% | $920K+244.3% | $8.5M | $0-100.0% | $11.9M | $267K | N/A | $150K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
APUS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -18.9%+8.4pp | -27.7% | N/A | -21.8% | -27.3% | N/A | N/A | N/A |
| Return on Assets | -15.8%+9.4pp | -24.8%+130.0pp | N/A | -19.3% | -25.2% | -154.8% | N/A | N/A |
| Current Ratio | 0.51-12.3x | 0.90+0.8x | 1.31+1.3x | 8.34 | 12.79 | 0.15 | 0.01-3.4x | N/A |
| Debt-to-Equity | 0.20+0.1x | 0.12 | 0.07 | 0.13 | 0.08 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. APUS | FY2025 | N/A | -$6.0M | N/A | $7.8M | — |
| AYTU BioPharma, Inc. AYTU | FY2026 | $57.6M | -$14.3M | -24.8% | $22.0M | 47/100 |
| Talphera, Inc. TLPH | FY2025 | $28K | -$14.3M | N/A | $56.1M | — |
| Gelteq Limited GELS | FY2025 | N/A | -$6.6M | N/A | $5.6M | — |
| Flora Growth Corp. FLGC | FY2025 | $35.7M | -$119.7M | N/A | $21.6M | 32/100 |
| TherapeuticsMD, Inc. TXMD | FY2025 | $3.0M | -$569K | -18.8% | $23.8M | 63/100 |
Where Apimeds Pharmaceuticals US, Inc. Ranks
Frequently Asked Questions
Is Apimeds Pharmaceuticals US, Inc. profitable?
No, Apimeds Pharmaceuticals US, Inc. (APUS) reported a net income of -$6.0M in fiscal year 2025.
What is Apimeds Pharmaceuticals US, Inc.'s EBITDA?
Apimeds Pharmaceuticals US, Inc. (APUS) had EBITDA of -$11.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Apimeds Pharmaceuticals US, Inc.'s return on equity (ROE)?
Apimeds Pharmaceuticals US, Inc. (APUS) has a return on equity of -3.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Apimeds Pharmaceuticals US, Inc.'s free cash flow?
Apimeds Pharmaceuticals US, Inc. (APUS) recorded an outflow of $9.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Apimeds Pharmaceuticals US, Inc.'s operating cash flow?
Apimeds Pharmaceuticals US, Inc. (APUS) recorded an outflow of $8.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Apimeds Pharmaceuticals US, Inc.'s total assets?
Apimeds Pharmaceuticals US, Inc. (APUS) had $164.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Apimeds Pharmaceuticals US, Inc.'s capital expenditures?
Apimeds Pharmaceuticals US, Inc. (APUS) invested $57K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Apimeds Pharmaceuticals US, Inc. spend on research and development?
Apimeds Pharmaceuticals US, Inc. (APUS) invested $1.6M in research and development during fiscal year 2025.
What is Apimeds Pharmaceuticals US, Inc.'s current ratio?
Apimeds Pharmaceuticals US, Inc. (APUS) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.
What is Apimeds Pharmaceuticals US, Inc.'s debt-to-equity ratio?
Apimeds Pharmaceuticals US, Inc. (APUS) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Apimeds Pharmaceuticals US, Inc.'s return on assets (ROA)?
Apimeds Pharmaceuticals US, Inc. (APUS) had a return on assets of -3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Apimeds Pharmaceuticals US, Inc.'s P/E ratio?
Apimeds Pharmaceuticals US, Inc. (APUS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.8M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Apimeds Pharmaceuticals US, Inc.'s price-to-sales ratio?
Apimeds Pharmaceuticals US, Inc. (APUS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.8M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Apimeds Pharmaceuticals US, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Apimeds Pharmaceuticals US, Inc. (APUS) held $3.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.9M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Apimeds Pharmaceuticals US, Inc.'s Piotroski F-Score?
Apimeds Pharmaceuticals US, Inc. (APUS) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Apimeds Pharmaceuticals US, Inc.'s earnings high quality?
Apimeds Pharmaceuticals US, Inc. (APUS) reported a net loss of $6.0M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Apimeds Pharmaceuticals US, Inc. cover its interest payments?
Apimeds Pharmaceuticals US, Inc. (APUS) reported an operating loss of $11.9M against $283K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.